Breaking Finance News

Deutsche Bank retained GlaxoSmithKline PLC (LON:GSK) to Hold in a statement released earlier today.

Deutsche Bank has retained GlaxoSmithKline PLC (LON:GSK) to Hold in a statement released on 2/09/2017.

On 2/8/2017, Liberum Capital released a statement on GlaxoSmithKline PLC (LON:GSK) maintained the target price at 1,900.00GBX that suggested an upside of 0.22%.

Having a price of 1,557.75GBX, GlaxoSmithKline PLC (LON:GSK) traded 0.89% higher on the day. With the last close down -0.45% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.06% over the same period. GSK has recorded a 50-day average of 1,556.68GBX and a two hundred day average of 1,598.00GBX. Volume of trade was up over the average, with 10,054,607 shares of GSK changing hands over the typical 8,000,590

Performance Chart

GlaxoSmithKline PLC (LON:GSK)

With a total market value of 0 GBX, GlaxoSmithKline PLC has price-earnings ratio of 85.53 with a one year low of 1,342.50GBX and a one year high of 1,745.56GBX .

A total of 24 equity analysts have released a research note on the company. 3 brokerages rating the stock a strong buy, 6 brokerages rating the stock a buy, 17 brokerages rating the stock a hold, 2 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of 1,577.33GBX.

Brief Synopsis On GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.